跳至主要內容

新聞與行事曆

新聞: 截至 2026-10-12
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。

已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。

標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-13

10月13日週二 · 今天

10月14日週三

過往

已發布 · 最新在前

8月29日週六

人事

04:23
Yahoo Finance

General Electric (GE) Names Claire McDonough As GE Vernova CFO

Claire McDonough was named chief financial officer of GE Vernova.

文章預覽

General Electric (GE) Names Claire McDonough As GE Vernova CFO Bailey Pemberton Sat, August 29, 2026 at 2:23 PM GMT+10 3 min read GE GEV RIVN General Electric (NYSE:GE) energy unit GE Vernova appoints Rivian CFO Claire McDonough as its new Chief Financial Officer. McDonough is set to leave electric vehicle maker Rivian to take up the CFO role at GE Vernova. The move marks a key leadership change for GE's recently separated energy focused business. Executive moves like this often reflect how large industrial groups are thinking about growth, capital allocation and technology. It can be useful t…

GE Vernova 開啟原文 ↗

8月28日週五

產品

17:40
USA Today

Eli Lilly's diabetes drug Mounjaro gets approval for a new use

The FDA cleared Eli Lilly's Mounjaro for a new use tied to lowering heart attack risk, expanding the label on its diabetes franchise.

文章預覽

HEALTHCARE U.S. Food and Drug Administration Add Topic Eli Lilly's diabetes drug Mounjaro gets approval for a new use Ken Alltucker USA TODAY Aug. 28, 2026, 1:40 p.m. ET Hear this story The Food and Drug Administration approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes. The approval gives consumers another option when seeking a GLP-1 medication to lower heart-related health risk. In 2024, the FDA approved Novo Nordisk's anti-obesity drug, Wegovy, to lower the risk of cardiovascular events such as heart attack and…

Eli Lilly and Company 開啟原文 ↗

產品

16:16
Yahoo Finance

Moderna and Merck cancer vaccine wins in late-stage trial

Moderna and Merck & Co.'s jointly developed individualized cancer vaccine reported a positive result in a late-stage trial, per the article. The readout is for the mRNA cancer-vaccine program the two companies co-develop, and follow-on coverage in the same sweep tied it to melanoma. No efficacy figures are given in the cited piece, so none are reproduced here.

文章預覽

Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial Fatima Gulzar Sat, August 29, 2026 at 2:16 AM GMT+10 4 min read MRNA MRK On August 19, 2026, Moderna, Inc. (NASDAQ: MRNA ) and Merck & Co., Inc. (NYSE: MRK ) said their personalized melanoma vaccine, intismeran, combined with Merck's Keytruda, met its goals in a Phase 3 trial of 1,137 patients. It reduced the risk of cancer recurrence and spread compared with Keytruda alone, Reuters reported. It is the first positive late-stage trial result for an mRNA cancer vaccine. Merck's Jane Healy called the result a "clinically meaningf…

Moderna 開啟原文 ↗

合作

15:41
TIME

NVIDIA's $12.9 billion Hugging Face deal

TIME reports on NVIDIA's $12.9 billion deal for Hugging Face and the open-source/open-weight model distribution strategy behind it. Hugging Face is not a company in this universe, so only NVIDIA is tagged. The only figure carried in the cited article's headline is the $12.9 billion deal value.

文章預覽

Nvidia has reportedly agreed to buy popular AI library Hugging Face for $12.9 billion. The deal is partly a hedge against an emerging threat: AI companies which consume enormous quantities of Nvidia hardware are increasingly developing chips of their own. In a future where AI becomes centralized in a small group of players with their own chips, those companies could demand lower prices from Nvidia or bypass it altogether. Hugging Face, an online hub where developers share open AI models and datasets, gives Nvidia a stake in an alternative future, where downloadable AI models allow startups and…

NVIDIA 開啟原文 ↗

財報

13:42
CNBC

Marvell shares tumble on soft outlook despite 37% revenue growth

CNBC reports Marvell Technology shares fell roughly 6% after its fiscal Q2 report, as the company's outlook underwhelmed investors even though revenue grew 37% year over year. Figures as stated by CNBC: 6% share decline, 37% revenue growth.

文章預覽

Skip Navigation Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Key Points Marvell Technology fell as its fiscal 2028 outlook underwhelmed investors. The chipmaker reported Thursday that its second-quarter revenue jumped 37% year-on-year. Analysts said investors had "elevated" expectations due to a recent deal with Google. In this article MRVL Follow your favorite stocks CREATE FREE ACCOUNT An aerial view of Marvell Headquarters in Santa Clara, California, United States on June 2, 2026. Tayfun Coskun | Anadolu | Getty Images Marvel…

Marvell Technology 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天